Latest news

• GSK’s ViiV gets US okay for two-drug HIV regimen

  GSK’ s ViiV gets US okay for two-drug HIV regimen. Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant. ... The US regulator gave a green light to Juluca, which combines ViiV’s integrase inhibitor Tivicay (dolutegravir) with a

• ViiV files two-drug HIV maintenance regimen

  inhibitor Edurant (rilpivirine) in the US and EU.

• Gilead gets EU nod for TAF-based triple therapy for HIV

  The once-daily, single-tablet combines TAF with emtricitabine - a dual therapy sold as Descovy - with Johnson &Johnson's Edurant (rilpivirine).

• ViiV and Janssen take long-acting HIV regimen into phase III

  The combination of ViiV's long-acting integrase inhibitor cabotegravir and Janssen's non-nucleoside reverse transcriptase inhibitor (RTI) Edurant (rilpivirine) was shown to suppress HIV levels as effectively as a

• ViiV and Janssen plan pivotal trials of monthly HIV treatment

  Cabotegravir is a long-acting, investigational integrase inhibitor, while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that is already sold by Janssen under the Edurant brand name.